Longitudinal study shows high healthcare costs in psoriasis patients, indicating the need for improved treatment access pathways.
Despite high healthcare costs, nearly half of the patients did not achieve clear/nearly clear skin. These data, in the context of reducing costs for biosimilars, may provide a basis to challenge care pathways and access criteria for 'high-cost' treatments.
No takes yet. Share an insight, caveat, or question.
Gribaleva et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: